These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
356 related articles for article (PubMed ID: 29272550)
1. Different contributions of chemokine N-terminal features attest to a different ligand binding mode and a bias towards activation of ACKR3/CXCR7 compared with CXCR4 and CXCR3. Szpakowska M; Nevins AM; Meyrath M; Rhainds D; D'huys T; Guité-Vinet F; Dupuis N; Gauthier PA; Counson M; Kleist A; St-Onge G; Hanson J; Schols D; Volkman BF; Heveker N; Chevigné A Br J Pharmacol; 2018 May; 175(9):1419-1438. PubMed ID: 29272550 [TBL] [Abstract][Full Text] [Related]
2. Mutational Analysis of Atypical Chemokine Receptor 3 (ACKR3/CXCR7) Interaction with Its Chemokine Ligands CXCL11 and CXCL12. Benredjem B; Girard M; Rhainds D; St-Onge G; Heveker N J Biol Chem; 2017 Jan; 292(1):31-42. PubMed ID: 27875312 [TBL] [Abstract][Full Text] [Related]
3. Common structural interactions between the receptors CXCR3, CXCR4 and CXCR7 complexed with their natural ligands, CXCL11 and CXCL12, by a modeling approach. Costantini S; Raucci R; De Vero T; Castello G; Colonna G Cytokine; 2013 Oct; 64(1):316-21. PubMed ID: 23773308 [TBL] [Abstract][Full Text] [Related]
4. Differential activity and selectivity of N-terminal modified CXCL12 chemokines at the CXCR4 and ACKR3 receptors. Jaracz-Ros A; Bernadat G; Cutolo P; Gallego C; Gustavsson M; Cecon E; Baleux F; Kufareva I; Handel TM; Bachelerie F; Levoye A J Leukoc Biol; 2020 Jun; 107(6):1123-1135. PubMed ID: 32374043 [TBL] [Abstract][Full Text] [Related]
6. Kinetics of CXCL12 binding to atypical chemokine receptor 3 reveal a role for the receptor N terminus in chemokine binding. Gustavsson M; Dyer DP; Zhao C; Handel TM Sci Signal; 2019 Sep; 12(598):. PubMed ID: 31506383 [TBL] [Abstract][Full Text] [Related]
7. Ligand-specific conformational transitions and intracellular transport are required for atypical chemokine receptor 3-mediated chemokine scavenging. Montpas N; St-Onge G; Nama N; Rhainds D; Benredjem B; Girard M; Hickson G; Pons V; Heveker N J Biol Chem; 2018 Jan; 293(3):893-905. PubMed ID: 29180449 [TBL] [Abstract][Full Text] [Related]
8. Characterization of a chimeric chemokine as a specific ligand for ACKR3. Ameti R; Melgrati S; Radice E; Cameroni E; Hub E; Thelen S; Rot A; Thelen M J Leukoc Biol; 2018 Aug; 104(2):391-400. PubMed ID: 29601107 [TBL] [Abstract][Full Text] [Related]
9. Mutational analysis of the extracellular disulphide bridges of the atypical chemokine receptor ACKR3/CXCR7 uncovers multiple binding and activation modes for its chemokine and endogenous non-chemokine agonists. Szpakowska M; Meyrath M; Reynders N; Counson M; Hanson J; Steyaert J; Chevigné A Biochem Pharmacol; 2018 Jul; 153():299-309. PubMed ID: 29530506 [TBL] [Abstract][Full Text] [Related]
15. Interactions of the chemokines CXCL11 and CXCL12 in human tumor cells. Koch C; Fischer NC; Puchert M; Engele J BMC Cancer; 2022 Dec; 22(1):1335. PubMed ID: 36539774 [TBL] [Abstract][Full Text] [Related]
16. The relevance of the chemokine receptor ACKR3/CXCR7 on CXCL12-mediated effects in cancers with a focus on virus-related cancers. Freitas C; Desnoyer A; Meuris F; Bachelerie F; Balabanian K; Machelon V Cytokine Growth Factor Rev; 2014 Jun; 25(3):307-16. PubMed ID: 24853339 [TBL] [Abstract][Full Text] [Related]
17. Constitutive and chemokine-dependent internalization and recycling of CXCR7 in breast cancer cells to degrade chemokine ligands. Luker KE; Steele JM; Mihalko LA; Ray P; Luker GD Oncogene; 2010 Aug; 29(32):4599-610. PubMed ID: 20531309 [TBL] [Abstract][Full Text] [Related]